HBW-3220

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameHBW-3220
Drug Alias NameHBW-3220HBW-3-10
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsAutoimmune DiseasesGlomerulonephritisLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHyperway Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHyperway Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGlomerulonephritisLymphoma, B-CellLymphoma, Non-Hodgkin +[4] 
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A